Cancer Treatment Patent Using Quinoline Derivative and Antibody
Summary
The USPTO published patent application US20260097030A1 on April 9, 2026, disclosing a therapeutic combination of a quinoline derivative and an antibody for treating cancer, specifically lung and liver tumors. The application names 14 inventors and was filed on April 11, 2025. This publication makes the application publicly available but does not grant any enforceable patent rights.
What changed
The USPTO published patent application US20260097030A1 disclosing a therapeutic combination of a quinoline derivative and an antibody for cancer treatment. The combination includes an immune checkpoint inhibitor and a tyrosine kinase inhibitor. The application specifies activity against lung and liver tumors.
Pharmaceutical manufacturers and healthcare providers in the oncology space should monitor this application as it progresses through examination. The publication provides visibility into potential future patent claims that could affect development of combination cancer therapies using quinoline derivatives.
What to do next
- Monitor for updates
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHOD OF TREATING CANCER USING A COMBINATION OF QUINOLINE DERIVATIVE AND ANTIBODY
Application US20260097030A1 Kind: A1 Apr 09, 2026
Inventors
Xin TIAN, Chen SHEN, Peng LYU, Xiangjian WANG, Xiquan ZHANG, Zheng LIU, Yu XIA, Xiaoping JIN, Baiyong LI, Zhongmin Maxwell WANG, Baohui HAN, Tianqing CHU, Hua ZHONG, Rong LI
Abstract
The present application provides a therapeutic combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The therapeutic combination in the present application shows good activity against lung tumor and liver tumor.
CPC Classifications
A61K 31/4709 A61K 39/3955 A61P 35/00
Filing Date
2025-04-11
Application No.
19176458
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.